Grail, Inc. (NL0)
Summary
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
GRAIL: Looking Beyond The NHS-Galleri Headline
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
US FDA to hold advisory meeting to review Grail's multi-cancer test
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.
Grail, Inc. (NL0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Grail, Inc. ever had a stock split?
Grail, Inc. Profile
| Professional Services Industry | Industrials Sector | Joshua J. Ofman CEO | XMUN Exchange | US3847471014 ISIN |
| US Country | 910 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
GRAIL, LLC is a cutting-edge biotechnology firm that has its sights set on revolutionizing the early detection of cancer, a significant leap in the battle against this disease. The company was originally founded as PSC15, Inc. but underwent a name change to GRAIL, LLC in January 2016. Since its inception in 2015, GRAIL has made significant strides in its mission, positioning itself at the forefront of cancer diagnostics research and development. Based in Menlo Park, California, GRAIL operates under the auspices of its parent company, Illumina, Inc., benefiting from its vast resources and expertise in the genomic sequencing arena. GRAIL's commitment to utilizing cutting-edge technology for the development of its products underscores its potential to make a substantial impact on public health by facilitating the early detection of cancer.
Products and Services
GRAIL, LLC has developed a suite of innovative products aimed at the early detection of cancer, each designed to address different stages of diagnosis and patient management. These include:
- Galleri: This groundbreaking screening test is tailored for asymptomatic individuals who are over 50 years of age. Galleri works by detecting signals in the blood that may indicate the presence of cancer, thereby allowing for early intervention before symptoms manifest. The test represents a significant advance in non-invasive cancer screening, offering a promising tool in the quest to reduce cancer mortality rates through early detection.
- Diagnostic Aid for Cancer (DAC): Specifically designed to expedite the diagnostic resolution for patients who have a clinical suspicion of cancer, the DAC serves as a crucial tool in the diagnostic process. By streamlining the pathway to diagnosis, this product aims to shorten the time between suspicion and confirmation of cancer, thus facilitating prompt access to treatment.
- Minimal Residual Disease and Other Post-Diagnostic Tests: In addition to its early detection and diagnostic assistance products, GRAIL is working on developing tests for minimal residual disease (MRD) and other post-diagnostic scenarios. These tests are geared towards monitoring cancer survivors for any signs of recurrence, as well as providing insights into the effectiveness of treatment. The development of MRD and post-diagnostic tests reflects GRAIL’s comprehensive approach to cancer management, from detection through to survivorship.
